ArticleBMC complementary medicine and therapies2025
Bioactivity-guided fractionation of Withania somnifera (L.) Dunal roots extract: evaluation of the anti-progressive potential on human Kelly neuroblastoma cell line.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundWithania somnifera (L.) Dunal, commonly known as ashwagandha, is a cornerstone of Ayurvedic medicine and has demonstrated anti-metastatic properties, including the ability to mitigate the cytotoxic effects of carcinogens and chemotherapeutic agents. Neuroblastoma (NB), a highly aggressive paediatric cancer, accounts for approximately 15% of childhood cancer-related deaths. Despite intensive treatment, over 50% of NB cases experience tumor recurrence and debilitating long-term effects. This study aimed to evaluate the anti-progression effects of W. somnifera root fractions on the human NB Kelly cell line at sub-cytotoxic concentrations and to identify the active bioactive constituents.
methodsW. somnifera roots were extracted using 95% ethanol and subsequently fractionated via vacuum liquid chromatography with a methanol-water gradient elution, yielding twelve fractions. Kelly cells were treated with each fraction at sub-cytotoxic concentrations, as determined by MTT assay. Treated cells were then subjected to transwell extracellular matrix invasion and fibronectin adhesion assays. Data were analysed using one-way ANOVA (GraphPad Prism), with statistical significance set at P ≤ 0.05. Bioactive fractions were further subfractionated by preparative HPLC, and major constituents were tentatively identified using GC-MS.
resultsFraction 9 (eluted with 70% methanol) exhibited the highest anti-invasive activity, whereas Fraction 10 (eluted with 80% methanol) demonstrated the most potent and statistically significant (P = 0.0409) anti-adhesive effect compared to vehicle-treated cells (0.5% DMSO). Subfraction analysis revealed that Subfraction 10/1 had a significant anti-adhesive effect (P = 0.0482), while subfractions 10/3 and 9/2 showed non-significant anti-adhesive effects. GC-MS analysis of subfractions 9/2, 10/1, and 10/3 revealed the presence of four previously unreported compounds in W. somnifera.
conclusionsConstituents of W. somnifera roots exhibit promising anti-metastatic activity against neuroblastoma cells, highlighting their potential to complement existing chemotherapeutic regimens and reduce associated long-term side effects. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.